Become a donor or member and support our work to advance access to medicines. For everyone. Everywhere
2021
European Commission is offering no meaningful solutions for equitable access
Clinical Trial Data and the Risk of Bias
Getting Hack to Reality
A Pandemic Response Lacking Moral Leadership
MPs and MEPs Call for TRIPS Waiver
Over 100 MEPs call for a TRIPS Waiver
Access to Medicines in Europe
2020
HAI’s Great Health Hack Delivers Great Ideas for Access to Meds
Europe Faces a Critical Time of Key Medicine Shortages Amidst a Pandemic
What do the next five years have in store for the European Medicines Agency?
Dutch institutions failing to register results of clinical trials
EU Must Not Miss its Chance on WHO Technology Pool
TRIPS-flexibilities in Health Crises and Beyond
HAI Follows Dutch Government Advice in Response to COVID-19
2018
What Role Can Civil Society Play in the European Regulatory Process?
Open Science for Health: Shaping the New Framework Programme
2017
EU-Mercosur Trade Agreement: A bad deal for transparency, policy coherence and access to medicines
European Commission Appoints Health Action International to HTA Network Stakeholder Pool
2016
Clinical Trial Data Transparency on Trial – EMA Under Pressure From Pharma Lawsuit
2015
HAI urges MEPs to support key amendments to TTIP resolution
The EU-US Trade Deal Could Leave Europeans Sick
2014
EMA policy on clinical data publication a step ahead, but falls short of true potential
Abysmal decisions: Why the EC’s medicinal units shouldn’t be moved to DG Industry
Democracy violation: European Commission rejects citizens’ initiative to stop TTIP and CETA
2011
DG Trade State of Play reveals EU's ambitions for IP protection in FTAs
2010